Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

STAR50 Jun 2026 Index Rebalance: Post-Implementation Review

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>CSI announced four ADDs and four DELETEs for STAR50, effective 15 Jun 2026. Bridge-window data is complete through 12 Jun 2026.</li>
<li>Yuanjie Semi led the ADD bridge gains, while Hua Hong Semiconductor reversed its pre-announcement gains. SICC had the weakest bridge performance among the DELETEs.</li>
<li>Historically, positive-bridge ADDs averaged weaker first-week returns. Negative-bridge DELETEs showed the most consistent first-week losses.</li>
</ul>


CSI announced four ADDs and four DELETEs for STAR50, effective 15 Jun 2026. Bridge-window data is complete through 12 Jun 2026.
Yuanjie Semi led the ADD bridge gains, while Hua Hong Semiconductor reversed its pre-announcement gains. SICC had the weakest bridge performance among the DELETEs.
Historically, positive-bridge ADDs averaged weaker first-week returns. Negative-bridge DELETEs showed the most consistent first-week losses.


Xiamen Amoytop Biotech Co Ltd (688278 CH)

Yuanjie Semiconductor Technology (688498 CH)

STAR50 Jun 2026 Index Rebalance: Pre-Implementation Update